SciCombinator

Discover the most talked about and latest scientific content & concepts.

S Lee, MT Nguyen, MG Currier, JB Jenkins, EA Strobert, AE Kajon, R Madan-Lala, YA Bochkov, JE Gern, K Roy, X Lu, DD Erdman, P Spearman and ML Moore
Abstract
As the predominant aetiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed that a monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. Here, we test the hypothesis that increasing virus input titres in polyvalent inactivated HRV vaccine may result in broad nAb responses. We show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. Thus, we have generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.
Tweets*
22
Facebook likes*
7
Reddit*
0
News coverage*
28
Blogs*
4
SC clicks
0
Concepts
Pleconaril, Rhesus Macaque, Antiviral drug, Rhinovirus, Primate, Immune system, Common cold, Influenza
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com